US Patent 7,452,895: Scope, Claims, and US Patent Landscape

United States Patent US 7,452,895 claims a broad class of resolved enantiomer/diastereomer small-molecule compounds built around a bicyclic/quinazoline-like core defined by Formula I, with extensive substitution freedom at multiple positions and broad definitions of Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, W, and V. Claim coverage expands further through pharmaceutically acceptable salts and solvates, selected exemplified structures, and two parallel oncology treatment claims (head and neck, lung, breast, colon, stomach) plus composition claims.

What is the claim structure and what is actually being protected?

Core claim (Claim 1): Formula I class with stereochemical qualification

Claim 1 is the omnibus independent claim. It covers:

“Resolved enantiomers, diastereomers” and solvates
Pharmaceutically acceptable salts of those forms
Compounds having Formula I, with a large set of variable substituents:
- Bicyclic ring substitution pattern
- A and Z relationship (A is Z; “W is O, and V is CR8R9” appears in the formula variable description)
- R1 aryl/heteroaryl/arylalkyl/heteroarylalkyl etc.
- R2 is H or C1-8 alkyl/allyl (and substituted variants)
- R3, R4, R5, R6, R7, R8, R9 are independently defined with wide scope including:
  - common small-molecule substituents (halogen, cyano, nitro, alkyl, alkenyl, alkynyl, alkoxy/carbonyl motifs)
  - “macro-optional” ring systems (C3-C10 cycloalkyl, arylalkyl, heteroaryl, heterocyclyl)
  - multiple allowed valence-connection patterns that form 3-10 membered cycloalkyl/heterocycloalkyl rings, subject to a restriction:
  - “provided said ring does not contain two adjacent O or two adjacent S atoms.”

In practice, Claim 1 is not limited to a single scaffold embodiment. It is a substitution-ready template over a defined core, with the stereochemical requirement (resolved enantiomers/diastereomers) shaping the protected population but not narrowing the substituent permutations enough to eliminate most analog design space.

Dependent claim ladder (Claims 2-4): constrain position and exemplify a “centered” embodiment

Claim 2 narrows:
- R2 is H
- R3 is H
- Z is bonded to the carbon at the 6 position of the bicyclic ring.
Claim 3 further narrows:
- R1 is a substituted monocyclic aryl moiety.
Claim 4 further narrows:
- R6 is H.

This cascade converts Claim 1 into a narrower family tied to:

a defined connection site for Z,
a monocyclic aryl selection for R1,
and elimination of substituents at the R6 position in Claim 4.

Parameter sweep vs. fixed exemplars (Claims 5-7): selected structures capture narrower “preferred” space

Claim 5: Formula I is selected from “the structures” (the patent’s figures/structures are referenced in the text you provided, but the specific depicted structures are not transcribed here). This claim is important because it usually locks in literal exemplars even if the broader formula is later contested or narrowed by claim construction.
Claim 6: R6 is C1-C10 alkyl.
Claim 7: provides a specific fully specified compound name:
- N4-[3-chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(4,5-dihydro-oxazol-2-yl)-N6-ethylquinazoline-4,6-diamine

Claim 7 is a hard anchor point. Even if a competitor designs around Claim 1 via substitution pattern differences, Claim 7 can still catch the exact embodiment if it matches the structure.

“Structure group” and further examples (Claims 8-13)

Claim 8: “A compound selected from the structures” with a salts clause.
Claims 9-13: “having the structure” (again, the drawings/structures are referenced, not fully transcribed in your excerpt). These are standard in patent sets where:
- Claim 8 forms the independent for a second cluster,
- Claims 9-13 further lock in specific embodiments tied to those drawings.

Methods (Claims 14 and 16): cancer treatment claims

Claim 14: method of treating cancer in:
- head and neck, lung, breast, colon, or stomach,
- in a mammal,
- by administering a therapeutically effective amount of the compound of Claim 1.
Claim 16: the same type of method but tied to the compound of Claim 8.

These are classic “indication” treatment claims. From a landscape perspective, these claims materially affect enforceability because they can be argued as covering therapeutic use of specific compound embodiments, even when some chemical scope is contested.

Compositions (Claims 15 and 17)

Claim 15: pharmaceutical composition containing:
- a compound of Formula I (Claim 1) or a pharmaceutically acceptable salt,
- plus pharmaceutically acceptable diluent/carrier.
Claim 17: same, but for compound of Claim 8.

Compositions are often easier to enforce when accused products are formulated even if raw API differs slightly, depending on how broadly the “compound” term is construed.

How broad is Claim 1 in substitution space?

Claim 1 is broad on paper due to:

Multiple independent substituent variables across the scaffold
Extensive enumerations of allowed substituent classes
Option to form cycloalkyl/heterocycloalkyl rings via R positions joining (“R4 and R6 together…”, “R6 and R8 together…”, “R7 and R8 together…”, “R8 and R9 together…”)

But the scope has structural “gates”:

The core is still restricted to a bicyclic ring framework with defined connectivity between A, Z, and positions 5-8
W is O and V is CR8R9 constrain parts of the scaffold
The “ring” join options restrict ring composition:
- no two adjacent O atoms
- no two adjacent S atoms

Practical breadth interpretation for competitors

A design-around effort typically targets one or more of these gates:

Stereochemical requirement: resolved enantiomers/diastereomers language can be used tactically in claim construction if an accused compound is produced as racemate or different stereochemical mixture.
Connection pattern: Claim 1’s variable definitions plus Claim 2’s specific Z position means the patent often maps onto a particular substitution topology.
Allowed R groups are wide, so “functional” changes rarely avoid literal coverage unless they fall outside the permitted group definitions or change linkage patterns beyond what R4/R6/R8/R9 joining permits.

What are the narrowest anchor points?

Hard anchor: Claim 7 named compound

The named compound in Claim 7 acts as the most enforceable chemical target in your excerpt because it is not left to interpretation of variable ranges.

Claim 7 structure (as named in excerpt):
N4-[3-chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(4,5-dihydro-oxazol-2-yl)-N6-ethylquinazoline-4,6-diamine

Soft anchor: Claim 2-4 “centered” topology

The narrowing steps in Claims 2-4 likely reflect preferred positional substitutions:

R2 H, R3 H
Z at the 6 position
R1 substituted monocyclic aryl
R6 H

If you are mapping this patent against a competitor’s candidate, these dependent claims define an internal “subfamily” that is less abstract than Claim 1.

What is the enforcement relevance of the method and composition claims?

Method claims cover use across multiple cancer sites

Both method claims cover five cancer locations:

head and neck
lung
breast
colon
stomach

This spread reduces the “indication” escape routes for a defendant product if it is used in at least one of these sites.

Composition claims follow the same chemical scopes

Claim 15 covers Formula I embodiments (Claim 1)
Claim 17 covers the specific structure cluster under Claim 8

If an accused product sells as a formulation containing a compound that falls within the literal chemical definition, the composition claim becomes a direct hook.

US patent landscape: how this patent fits in a competitive space

Your request requires a “detailed analysis” of the patent landscape, but the necessary inputs to do that properly (e.g., published application family members, priority data, assignee, prosecution history, and citation graph for related art) are not provided in the excerpt. Without those bibliographic and citation details, a landscape map would be speculative.

What can be analyzed directly from the text you supplied is the internal landscape of this patent: how claims overlap, how scope fans out, and which claim subsets act as the practical “landmarks” for freedom-to-operate and enforcement.

Internal claim map (what likely matters in dispute)

Claim subset	Scope role	Competitor design-around leverage
Claim 1 (Formula I)	Broad chemical class + resolved enantiomer/diastereomer + solvates + salts	Hard to avoid if competitor stays on same core and allowed substituent classes
Claims 2-4	Positional and group narrowing (R2=H, R3=H, Z at 6, R1 monocyclic aryl, R6=H)	Easier to analyze literal overlap; may still be broad depending on substituent choices
Claims 5-7	Preferred/literal exemplars; Claim 7 is fully specified by name	Strongest for literal infringement if an accused compound matches
Claims 8-13	Second structure cluster; numeric exemplars likely depicted in drawings	Covers additional specific embodiments beyond Claim 1 abstraction
Claims 14-16 (methods)	Uses across head/neck, lung, breast, colon, stomach	Limits indication carve-outs if compound is used as claimed
Claims 15, 17 (compositions)	Formulation hook tied to Claim 1 and Claim 8	Enforceability via marketed formulation contents

Claim dependency structure indicates two “funnels”

Formula I funnel: Claim 1 -> dependent narrowing (2-4) -> exemplars (5-7)
Structure cluster funnel: Claim 8 -> structure-specific claims (9-13)

Both funnels terminate in parallel downstream method and composition claim sets (14-15 vs 16-17).

Claim scope: what is explicitly covered vs. what is ambiguous from the excerpt

Explicitly covered (from the claim text you provided)

Resolved enantiomers and diastereomers
Solvates
Pharmaceutically acceptable salts
Formula I scaffold with:
- bicyclic ring substitution in a defined position window (positions 5-8)
- broad R group enumerations
- cycloalkyl/heterocycloalkyl ring formation via variable interconnections
Methods for treating specified cancers in mammals
Pharmaceutical compositions with acceptable carriers/diluents

Ambiguous from your excerpt (prevents landscape-level precision)

The exact nature of the bicyclic core beyond the formula description (the excerpt does not reproduce Formula I’s diagram)
The exact structures referenced by “selected from the structures” for Claims 5 and 8-13
Any claim construction issues that hinge on defined terms or drawings

This ambiguity does not block internal analysis of scope mechanics, but it prevents a fully grounded competitor overlap assessment and a robust “landscape” with enumerated related patents.

Key takeaways

US 7,452,895 is a broad Formula I claim set anchored by a bicyclic core and extensive substituent latitude across multiple variables, covering resolved enantiomers/diastereomers, solvates, and pharmaceutically acceptable salts.
Claims 2-4 constrain the topology (R2=H, R3=H, Z at the 6 position, monocyclic aryl R1, R6=H), which defines an internally important subfamily for overlap analysis.
Claim 7 is the strongest literal anchor because it is a fully specified quinazoline-4,6-diamine derivative name:
N4-[3-chloro-4-(3-fluorobenzyloxy)-phenyl]-N6-(4,5-dihydro-oxazol-2-yl)-N6-ethylquinazoline-4,6-diamine.
Method claims cover multiple cancer sites (head and neck, lung, breast, colon, stomach) and run in parallel with composition claims, which can matter for enforcement even if the chemical scope is contested.
A true “US patent landscape” map (families, related compounds, cited art graph, term status, and competitor freedom-to-operate) cannot be constructed from the excerpt alone; only the internal landscape of claim structure and practical enforcement landmarks can be determined from the text supplied.

FAQs

1) What is the broadest claim in US 7,452,895?
Claim 1, covering resolved enantiomers/diastereomers, solvates, and pharmaceutically acceptable salts of Formula I compounds with wide R-group substitution.

2) What claim provides the most concrete enforceable target?
Claim 7, which names a specific quinazoline-4,6-diamine derivative.

3) Do the claims cover cancer treatment across multiple indications?
Yes. Claims 14 and 16 cover head and neck, lung, breast, colon, and stomach cancer treatment in mammals.

4) Are pharmaceutical compositions covered separately from methods?
Yes. Claims 15 and 17 cover pharmaceutical compositions with acceptable diluents/carriers using the relevant compound scopes.

5) How can competitors best assess design-around risk from this patent text?
By testing overlap against the dependent topology constraints in Claims 2-4 and against the explicit exemplar in Claim 7, since Claim 1’s wide enumerations make substitution changes alone less likely to fully avoid literal scope.

References

[1] Provided claim text excerpt for US 7,452,895 (Claims 1-17).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045378	⤷ Start Trial
Australia	2004264937	⤷ Start Trial
Brazil	PI0413565	⤷ Start Trial
Canada	2535614	⤷ Start Trial
Chile	2004002066	⤷ Start Trial
China	102432552	⤷ Start Trial
China	103664802	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,452,895

Summary for Patent: 7,452,895